Recent News

• 07.25.2025 - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
• 07.25.2025 - Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
• 07.23.2025 - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
• 07.23.2025 - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
• 07.15.2025 - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
• 07.15.2025 - Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
• 07.11.2025 - Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
• 07.11.2025 - Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Recent Filings

• 07.22.2025 - 8-K Current report
• 07.18.2025 - D Notice of Exempt Offering of Securities
• 07.16.2025 - 8-K Current report
• 07.15.2025 - 8-K Current report
• 07.15.2025 - EX-99.1 EX-99.1
• 07.11.2025 - 425 Prospectuses and communications, business combinations
• 07.11.2025 - 8-K Current report
• 07.11.2025 - EX-99.1 EX-99.1
• 07.01.2025 - 425 Prospectuses and communications, business combinations
• 07.01.2025 - EX-99.1 EX-99.1